SO YOUNG•Financial Summary•AI-Powered Insights

SO YOUNG 2026 Q1
Earnings Overview & AI Insights

Detailed performance report for SO YOUNG covering Q1 2026. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.

SO YOUNG (2026 Q1)

Earnings Performance

No Performance Data

Summary of Financial Performance: Q1 2026 revenue rose 45.6% YoY to RMB 432.8 million, driven by strong growth in branded aesthetic center operations. Aesthetic treatment service revenue increased 185.8% YoY to RMB 282.4 million and represented over 65% of total revenue, with gross margin up 8.4 percentage points YoY and 3.3 points QoQ. Medical products and maintenance revenue grew 2.8% YoY to RMB 57.1 million, while information/reservation and other services declined. Total operating expenses increased 26.6% YoY to RMB 239.7 million, but slower than revenue growth. Net loss widened to RMB 49.2 million, and non-GAAP net loss was RMB 46.6 million. Cash and investments totaled RMB 880 million at quarter-end.

Company Outlook & Strategy: Management reiterated confidence in the branded aesthetic center model and expects Q2 2026 aesthetic treatment service revenue of RMB 307 million to RMB 317 million, implying 112.6% to 119.5% YoY growth. Strategy remains focused on supply chain optimization, medical delivery excellence, and operating efficiency to support a path to profitability. The company plans to continue measured expansion toward its 1,000-center goal while improving standardization, profitability, and shareholder value.

Key Industry Trends: Management described China’s medical aesthetics market as entering a more mature, competitive phase with greater price transparency and accelerated upstream supply, especially in categories such as PLLA and collagen. Consumer preferences are shifting toward anti-aging, more rational spending, and broader adoption in lower-tier cities. Light medical aesthetics now makes up nearly 80% of the market, and the company believes the segment has substantial long-term growth potential.

Operational Highlights: The company operated 54 So-Young Clinics across 16 major cities, adding 5 centers during the quarter. 41 centers were profitable and 48 generated positive operating cash flow, reflecting improved scale and maturity. New product launches included Miracle Collagen, enhanced collagen, and Sakura skin booster version 2, supported by upstream partnerships and the Green Label system. Revenue from blockbuster products reached 41% of Q1 revenue, led by BBL and Thermage. The company also highlighted physician-led consultation rollout, AI-enabled diagnosis tools, and a Beijing physician training/R&D center to improve consistency and efficiency.

Challenges & Risks: Management acknowledged intense industry competition and the exit of weaker players. Operating expenses, especially sales/marketing and G&A, rose meaningfully due to expansion and user acquisition. The company also noted lower revenue in information/reservation services and other services. Talent retention remains an ongoing focus, with physician turnover described as in line with industry averages, not below it.

Key Analyst Questions & Responses: Analysts asked about industry slowdown, ARPU expansion, talent retention, and service model innovation. Management responded that structural opportunities remain large, with demand driven by anti-aging, more rational consumers, and rising penetration in lower-tier cities. ARPU should grow through premium services for core members, expanded mid- to high-end offerings, and bundled treatment solutions. Blockbuster products like Thermage, BBL, and collagen-based offerings were highlighted as key growth drivers. On talent, management emphasized rigorous hiring, training, compensation, career progression, and equity incentives. On operations, the company said physician-led consultations, standardized treatment templates, and AI-enabled tools will improve trust, conversion, and efficiency.

Earnings Call Transcript

Access the official earnings call transcript for SO-YOUNG 2026 Q1. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.